NVIDIA launches Jetson Thor robotics computers for physical AI systems
In a recent transaction reported to the Securities and Exchange Commission, Gilbert A. Fuller, a director at USANA Health Sciences Inc . (NYSE:USNA), sold 674 shares of common stock. The shares were sold at an average price of $31.4398 each, totaling approximately $21,190. Following this sale, Fuller no longer holds any shares directly in the company. This transaction was filed with the SEC on March 10, 2025, reflecting activity from March 6, 2025.The stock has since risen to $33.49, showing a strong 9.94% gain over the past week. InvestingPro data reveals USANA maintains impressive gross profit margins of 81% and holds more cash than debt on its balance sheet, indicating solid financial health. According to InvestingPro’s Fair Value analysis, the stock currently appears undervalued.Want deeper insights? InvestingPro offers 8 additional key tips for USANA Health Sciences, along with comprehensive financial analysis in its Pro Research Report, helping investors make more informed decisions.
In other recent news, USANA Health Sciences reported its fourth-quarter 2024 earnings, which exceeded analyst expectations with an earnings per share (EPS) of $0.64, surpassing the forecasted $0.49. The company also reported revenue of $214 million, which was higher than the anticipated $208.84 million. Despite this positive performance, USANA’s guidance for fiscal year 2025 has raised concerns among investors. The company projected earnings per share between $2.35 and $3.00, which fell short of the consensus estimate of $2.87. Additionally, the forecasted revenue range of $920-1000 million for FY2025 only brackets the consensus estimate of $934.5 million.
USANA’s acquisition of Hiya Health contributed to the fourth-quarter results, although its impact was minimal due to the timing of the acquisition. The company plans to launch over 20 new products in 2025 and expects Hiya Health’s revenue to grow by 29-42%, reaching $145-$160 million. Analysts have noted that the integration of Hiya Health poses operational risks. USANA’s President and CEO, Jim Brown, expressed optimism about the company’s growth strategy, which includes supporting its Associate sales force and implementing new initiatives for long-term growth.
Looking ahead, USANA anticipates net sales growth of 8% to 17% for 2025, with projected net earnings between $29 million and $41 million. The company also plans to host a global convention in Salt Lake City and introduce a new associate incentive program in the latter half of the year. Despite challenges in key markets like China, USANA’s leadership remains confident in their strategic initiatives to drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.